Home Newsfeeds Benchmark Downgrades Invitae to Hold

Benchmark Downgrades Invitae to Hold

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

byBenzinga Newsdesk

July 19, 2022

1 minute read

Benchmark analyst Bruce Jackson downgrades Invitae (NYSE:NVTA) from Buy to Hold.

Analyst Ratings

Where Methanex Stands With Analysts

By Benzinga Insights

July 11, 12:00 PM

Analysts have provided the following ratings for Methanex (NASDAQ:MEOH) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

MEOH

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

By Lisa Levin

September 22, 6:34 AM

Gainers Spero Therapeutics, Inc. (NASDAQ: SPRO) rose 105.6% to $1.69 in pre-market trading. GSK and Spero Therapeutics announced exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.

ACOR

Why Are Panbela Therapeutics Shares Trading Higher Today?

By Vandana Singh

July 19, 12:18 PM

Panbela Therapeutics Inc (NASDAQ: PBLA) shares are trading higher after the company divested certain assets in its eflornithine pediatric neuroblastoma program to US WorldMeds 1 (USWM), a Kentucky-based

PBLA

What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?

By Vandana Singh

June 5, 3:17 PM

Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.

AKRO

Benchmark Downgrades Invitae to Hold

Related Posts

Where Methanex Stands With Analysts

Why Spero Therapeutics Is Trading Higher By Over 105%; Here Are 21 Stocks Moving Premarket

Why Are Panbela Therapeutics Shares Trading Higher Today?

What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?